Skip to main content
OpenTrials

Clinical trial condition

Plasma Cell Myeloma

Explore clinical trials studying Plasma Cell Myeloma. Study availability and eligibility vary by location and protocol.

79 public trials 8 recruiting studies
Refine in advanced search Browse all conditions

Plasma Cell Myeloma trial results

Completed

Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients

NCT02990338

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • BRCR Medical Center Inc. Site Number : 8400002 Plantation, Florida, United States
  • Dana Farber Site Number : 8400006 Boston, Massachusetts, United States
  • Investigational Site Number : 0360004 St Leonards, New South Wales, Australia
  • Investigational Site Number : 0360001 Waratah, New South Wales, Australia
View all 111 locations
View Trial Details
Completed

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

NCT03194867

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • University of Colorado-Site Number:8400001 Denver, Colorado, United States
  • University of Kansas Medical Center-Site Number:8400003 Kansas City, Kansas, United States
  • Memorial Sloan-Kettering Cancer Center-Site Number:8400002 New York, United States
  • Fox Chase Cancer Center-Site Number:8400004 Philadelphia, Pennsylvania, United States
View all 30 locations
View Trial Details
Completed

Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

NCT02513186

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Investigational Site Number : 250002 Nantes, France
  • Investigational Site Number : 250003 Pierre-Bénite, France
  • Investigational Site Number : 250001 Toulouse, France
  • Investigational Site Number : 276003 Berlin, Germany
View Trial Details
Completed

SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients

NCT01749969

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Investigational Site Number 840004 San Francisco, California, United States
  • Investigational Site Number 840001 Tampa, Florida, United States
  • Investigational Site Number 840002 St Louis, Missouri, United States
  • Investigational Site Number 840005 New York, United States
View Trial Details

Related conditions